Life Sciences In The Spotlight As UK Prepares For General Election
The opposition Labour Party’s life sciences plan aims to make the UK a “frontier market” for innovative products, including cell and gene therapies.
You may also be interested in...
The ABPI’s “manifesto for investment, health and growth” says that the new government to be elected later this year must ensure that investment in new medicines and research accelerates future innovation and attracts more R&D to the UK.
The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.
A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.